Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 135 |
| Active Pipeline (Recruiting Now) | 55 (29) |
| Completed vs Stopped Early | 15 / 5 (3.7%) |
| Median Closed Actual Enrollment | 74 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking University People's Hospital | Beijing, Beijing Municipality | 52 |
| Peking University First Hospital | Beijing, Beijing Municipality | 6 |
| Peking University Third Hospital | Beijing, Beijing Municipality | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07796516 | Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Peking University People's Hospital Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.